Bellevue Life Sciences Acquisition registered an offering of 6 million units to be priced at $10 each. A unit consists of a share and a warrant, exercisable at $11.50.
The new SPAC’s focus is on the biotechnology sector.
CEO and Director Kuk Hyoun Hwang is the managing partner of BCM, which he founded in August 2012. BCM is the South Korea advisor for BAM, a subsidiary of Bellevue Group AG, a Swiss financial group holding company with global healthcare investing expertise which is publicly listed on the Swiss Exchange and oversees assets under management of approximately $11 billion
Chardan is sole book-running manager for the SPAC’s offering.
The SPAC intends to apply for a Nasdaq listing under the symbol BLACU. Read more.
